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ABSTRACT
Background and aims Estimating ‘return on investment’ (ROI) from smoking cessation interventions requires reach
and effectiveness parameters for interventions for use in economic models such as the EQUIPT ROI tool (http://roi.
equipt.eu). This paper describes the derivation of these parameter estimates for England that can be adapted to create
ROI models for use by other countries. Methods Estimates were derived for interventions in terms of their reach and
effectiveness in: (1) promoting quit attempts and (2) improving the success of quit attempts (abstinence for at least
12 months). The sources were systematic reviews of efﬁcacy supplemented by individual effectiveness evaluations and
national surveys. Findings Quit attempt rates were estimated to be increased by the following percentages (with reach
in parentheses): 20% by tax increases raising the cost of smoking 5% above the cost of living index (100%); 10% by
enforced comprehensive indoor public smoking bans (100%); 3% by mass media campaigns achieving 400 gross rating
points (100%); 40% by brief opportunistic physician advice (21%); and 110% by use of a licensed nicotine product to
reduce cigarette consumption (12%). Quit success rates were estimated to be increased by the following ratios: 60% by
single-form nicotine replacement therapy (NRT) (5%); 114% by NRT patch plus a faster-acting NRT (2%);124% by
prescribed varenicline (5%); 60% by bupropion (1%); 100% by nortriptyline (0%), 10) 298% by cytisine (0%); 40% by in-
dividual face-to-face behavioural support (2%); 37% by telephone support (0.5%); 88% by group behavioural support
(1%); 63% by text messaging (0.5%); and 19% by printed self-help materials (1%). There was insufﬁcient evidence to
obtain reliable, country-speciﬁc estimates for interventions such as websites, smartphone applications and e-cigarettes.
Conclusions Tax increases, indoor smoking bans, brief opportunistic physician advice and use of nicotine replacement
therapy (NRT) for smoking reduction can all increase population quit attempt rates. Quit success rates can be increased by
provision of NRT, varenicline, bupropion, nortriptyline, cytisine and behavioural support delivered through a variety of
modalities. Parameter estimates for the effectiveness and reach of these interventions can contribute to return on
investment estimates in support of national or regional policy decisions.
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INTRODUCTION
‘Return on investment’ (ROI) estimates for public health in-
terventions can inform resource allocation decisions use-
fully at national or regional levels [1]. They are
dependent upon estimates of the effectiveness and reach
of the interventions being evaluated. Interventions to
promote smoking cessation are recognized as particularly
important in public health [2]. They include a range of ap-
proaches from education and persuasion to restrictions
and support services [3]. This paper describes the processes
and outcomes of an exercise to arrive at reach and effect-
size estimates for cigarette smoking cessation interventions
undertaken to inform development of a Europe-wide ROI
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calculation tool (EQUIPT) [4]. Cigarettes are the most com-
monly used tobacco product and the one for which there is
the most evidence, so the scope of this review is limited to
cigarette smoking.
Developing a strategy to promote smoking cessation
can be based usefully on an evaluation of the probable im-
pact of the components of that strategy relative to their
cost. Cost-effectiveness (CE) estimation is usually expressed
in terms of cost per ‘quality-adjusted’ life-year gained,
‘disability-adjusted’ life-year gained or sometimes simply
life-year gained [5]. In the case of smoking cessation there
are ﬁnancial savings; for example, from not having to treat
smoking-related illnesses, and from less time lost to sick-
ness absence and time off work for cigarette breaks [6].
This means that one can go further than estimating cost-
effectiveness from a health service perspective to making
a judgement about ‘cost–beneﬁt’ from a wider perspective
(CB) [5]. When it comes to developing policies, CB
estimates can then be used to estimate the overall ‘return
on investment’ (ROI) [7]: the economic beneﬁt for a given
jurisdiction such as a region or country over a given
time-scale. This will depend upon the size of the
population, the prevalence of smoking and the population’s
demographic characteristics.
Both CB, and therefore ROI, estimates depend upon
assumptions about the effects of the interventions in
promoting smoking cessation in a real-world setting.
Effectiveness of behaviour change interventions is often
context-sensitive and depends upon speciﬁc features of
those interventions [8]. This means that effect-size
estimates from studies in the research literature require a
set of assumptions in order to be translated into effective-
ness estimates in populations. A systematic process needs
to be adopted for this, and the resulting estimates need to
be qualiﬁed accordingly to ensure their ﬁtness for the
speciﬁc purpose of any research endeavour.
ROI estimates also depend upon the reach of interven-
tions. A highly effective intervention that reaches a small
only proportion of the target population may have a lower
overall ‘impact’ (reach × effectiveness) than an interven-
tion with a small effect but to which a large proportion of
the population is exposed [9]. Reach can also be important
for the cost part of CB estimation. Some interventions, such
as mass media campaigns, have substantial ﬁxed costs and
so may be highly cost-beneﬁcial when reach is high, but
not if reach is low.
Effectiveness and reach of smoking cessation interven-
tions have been estimated in several reviews, and the
ﬁndings incorporated into CB or ROI estimation exercises
[10–22]. However, as evidence accumulates we can make
improved estimates for interventions already known about,
add estimates for new interventions or new versions of
interventions and revise estimates for interventions to take
account of varying context.
The proportion of a population that stops smoking in a
given time-period is the proportion who try to quit multi-
plied by the proportion of those who maintain abstinence
[23]. These two parts of the process involve different mech-
anisms and are subject to different modiﬁers [24]. Different
interventions may have different effects on these two parts
of the process of cessation, so modelling the impact of
smoking cessation interventions needs to recognize this.
Therefore, parameter estimates for effectiveness and reach
of smoking cessation interventions need to relate sepa-
rately to these two components of cessation.
Through the Smoking Toolkit Study (STS) [25], En-
gland has unique data on large, nationally representative
samples of smokers and recent ex-smokers that are up-
dated every month. The STS provides real-world estimates
of effectiveness of interventions on quit attempts and quit
success as well as up-to-date estimates of reach in a coun-
try that has a strong tobacco control climate. The effect-
size estimates can be used to check how far ﬁndings from
randomized controlled trials (RCTs) or other experimental
studies translate into a national setting, and the reach esti-
mates can provide a benchmark for modelling in countries
for which such data are not available.
This paper reports the process used to arrive at up-to-
date effectiveness (in terms of quit attempts and quit
success) and reach estimates for smoking cessation inter-
ventions, using England as a case example. It presents the
estimates relating to a wide range of interventions
together with rationales and caveats. The parameters
derived from this process have been incorporated into a
spreadsheet and combined with cost and health outcome
data to generate ROI estimates in EQUIPT. Any of the
parameters are potentially modiﬁable, so that individual
countries can reﬂect their own local data and
circumstances.
METHODS
We ﬁrst identiﬁed interventions that were judged suitable
for inclusion and speciﬁed versions of these for which
effect-size estimates could be derived. We then assessed
the reach of those interventions in England, and ﬁnally
carried out effectiveness estimation.
Identiﬁcation of interventions to be evaluated
We ﬁrst identiﬁed broad types of smoking cessation inter-
ventions for which it was judged to be possible to arrive
at effectiveness estimates. Effectiveness estimates can only
be derived from: (1) randomized controlled trials (RCTs),
(2) quasi-experimental studies, (3) comparative observa-
tional studies or, in the case of population-level interven-
tions, (4) time–series analyses. We excluded interventions
in which evidence was judged insufﬁcient for conﬁdent
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effect-size estimation at the time ofwriting (e.g. e-cigarettes
with only two small RCTs and one large real-world study,
standardized packing where it was too early to be able to
estimate an effect with conﬁdence, nicotine replacement
therapy pre-loading where results are not sufﬁciently
conclusive, internet applications where the results show
large unexplained heterogeneity and smartphone applica-
tions where we lack published RCTs of sufﬁcient power).
The lead author had recently undertaken a major
review of clinical interventions that combined evidence,
primarily from Cochrane Reviews acknowledged to be of
high quality, with additional RCT evidence and evidence
from real-world evaluations being checked to conﬁrm the
estimates from the reviews [23]. It included screening
clinical interventions for those that were effective and
where the effect size could be estimated.
For population-level interventions, we began by
searching for those that had been reviewed by Cochrane,
and then undertook a review of reviews to assess whether
there were any additional interventions that could be
included. This involved searching Pubmed and Web of
Science using the terms ‘Tobacco control’ + ‘interven-
tion’+ ‘review’.We identiﬁed reviews fromwhichwe could
derive effect-size estimates for quit attempts or quit success.
We excluded reviews that focused on: (1) speciﬁc sub-
groups such as women, smokers with psychiatric disorders
(e.g. [26]) or smokers with substance use disorders
(because of lack of evidence for differential effectiveness);
(2) outcomes other than overall effect sizes (e.g. health in-
equalities [27,28]); (3) particular behavioural techniques,
such as motivational interviewing [29]; and (4) smoking
initiation [30].
Having identiﬁed broad types of smoking cessation in-
terventions, we then sought to characterize a particular
variant of that intervention for use in the effectiveness
and reach estimation. Thus, any of the interventions could
take a wide variety forms in terms of the way they are de-
livered and their intensity. For example, increasing tax on
tobacco products can be undertaken in many ways and
by varying amounts. Given that the effect depends critically
upon this translating into an increase in the ﬁnancial cost
of smoking, it is essential to capture this feature of the tax
increase in the description of the intervention. Similarly,
massmedia campaigns can take different forms and to very
different levels of intensity. We needed to arrive at a speciﬁc
case that could be used for modelling purposes.
The process for arriving at speciﬁc variants of the inter-
vention types involved analysing the key ingredients of the
intervention and the typical level of intensity, and specify-
ing this at a level of descriptive detail that could guide the
development of new instances of that intervention type.
For each intervention type, the rationale for specifying a
given variant and the caveats attached to the choices made
are reported in this paper.
Reach estimation
Reach of the interventions was estimated using data
from the Smoking Toolkit Study [25], in the case of inter-
ventions that required health professionals to deliver them,
or smokers to engage actively with them. These estimates
are made available on a monthly basis at Smoking in
England website (www.smokinginengland.info). We used
ﬁgures for 2016 published on the website.
In the case of population-level measures it was as-
sumed to be 100%. This did not mean that we assumed
that all smokers would be exposed to the intervention,
but rather that the effect-size estimate already captured
the extent to which reach may have been less than
100%. For example, tax increases leading to a given in-
crease on the cost of smoking may not have done so for
all smokers because of cost-minimizing strategies, such
as switching to hand-rolled tobacco, reducing the number
of cigarettes consumed or purchasing from illicit sources.
However, the effect size from studies will have already
taken into account those strategies as they were enacted
at the time.
Effectiveness estimation
For the purpose of ROI modelling, effectiveness estimation
needed to be expressed using a single metric that could be
applied to varying contexts. Given that the outcomes
(making an attempt to stop and success of that attempt)
were binary, many of the reviews expressed effects in terms
of odds ratios. Quit attempts have been deﬁned variously in
the research literature, but refer generally to a serious
attempt to stop smoking permanently. In some studies,
the deﬁnition also requires at least 24 hours of abstinence.
Quit success is also subject to multiple deﬁnitions. Given
that ROI modelling assumes that abstinence is permanent,
the outcomemeasure needs to be predictive of lasting absti-
nence. Longitudinal studies of smoking cessation have
shown that 12 months of continuous abstinence provides
a reasonably accurate estimation of permanent cessation,
with approximately 70% of those who are abstinent for
12 months managing to maintain this for many years
[31]. Most of the studies included in Cochrane Reviews
use 12 months as the ﬁnal follow-up point. For compre-
hensibility and to ease the combination of attempt rates
and success rates to arrive at overall cessation rates, we
converted odds ratios (OR)where theywere used to relative
risks (RR) using the formula RR = OR/[(1–P) + (P × OR)],
where P is the probability of the outcome of interest in the
non-exposed/control group, obtained from the source that
provided the OR.
In the case of the clinical interventions, we were able to
draw upon the methods and ﬁndings from the review
undertaken previously by the lead author [23]. This review
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started with efﬁcacy estimates from Cochrane Reviews and
assessed how far evidence from real-world studies could be
expected to translate into outcomes in routine clinical
practice. We sought out the most recent reviews in order
to update the estimates or, if reviews were not available,
the most recent individual studies.
In the case of the population-level interventions, we
started with estimates from the most recent reviews and
compared these with ﬁndings from earlier ones to assess
the stability of the estimates. In some cases, the reviews
did not differentiate between effects on quit attempts and
quit success. In those cases we sought out studies that
did make this differentiation. If there were none, we made
an assumption that all the effect was on one or the other.
This assumption may not have been correct (e.g. there
may have been an effect on both attempt and success
rates), but this would not have an impact on the overall
cessation rates produced by combining attempt and
success rate in the ROI model as it was derived from those
overall cessation rates.
RESULTS
Table 1 gives the speciﬁcation of the interventions included
in the review and the justiﬁcation for the speciﬁcation
adopted. In all cases they are included because there is suf-
ﬁcient evidence to be able tomake an effect-size estimation.
The interventions are classiﬁed according to whether they
are modelled as increasing the quit attempt rate or the quit
success rate.
Table 2 shows interventions that were not included
despite there being studies conducted on their effective-
ness. It also provides justiﬁcation for their exclusion. The
main reason was an inability to make a conﬁdent
assessment of the effect size. This does not mean that there
was no effect: only that if there is an effect, its size remains
uncertain.
Table 3 shows the estimated reach and effect sizes of the
interventions together with supporting reference and
rationale. The effect-size estimates cannot be compared
directly with each other because they relate to different
input metrics. However, they provide a broad indication
of the probable impact of different contributions to a
tobacco control strategy. In many cases they are subject
to a wide degree of uncertainty, as indicated in Table 3.
This is more the case for population-level interventions,
partly because themethods used to generate the effect sizes
lead to greater uncertainty.
Table 4 shows caveats attaching to reach and effect-size
estimates in Table 3. It should be noted that the effect-size
and reach estimates reported here may differ from the
default values in the EQUIPTmodel. The estimates in this pa-
per are the most up-to-date available at the time of writing.
While the clinical interventions to support cessation
have relatively low reach, the effect-size estimates aremore
robust and they appear to be subject to somewhat less
variation than the population-level interventions.
DISCUSSION
Summary of key ﬁndings
A wide range of smoking cessation interventions were
identiﬁed for which it was judged possible to derive effect-
size estimates in relation to quit attempts or success of quit
attempts. In terms of interventions to increase the rate of
quit attempts these were: tax increases and associated
measures to increase the ﬁnancial cost of smoking, intro-
duction of comprehensive public indoor smoking bans,
mass media campaigns, brief opportunistic advice from
health professionals and use of licensed nicotine products
for smoking reduction. In terms of interventions to in-
crease the success rate of quit attempts the interventions
identiﬁed were: NRT (single form), NRT (dual form),
varenicline (standard duration), varenicline (extended du-
ration), bupropion, nortiptyline, cytisine, behavioural sup-
port (individual face-to-face), behavioural support (group
face-to-face), behavioural support (proactive telephone),
behavioural support (text messaging) and behavioural sup-
port (printed materials). While the effect-size estimates are
subject to a number of caveats, there can be a high degree
of conﬁdence that each of these interventions, if delivered
as speciﬁed in a way that is appropriate to the context, will
make a signiﬁcant contribution to increasing population
smoking cessation rates.
Relationship between ﬁndings and previous research
Most of the interventions identiﬁed in this review are simi-
lar to ones shown previously to be important in reducing
smoking prevalence. However, there were some additions,
including differentiating single- and dual-form NRT and
standard- and extended-duration varenicline. We also in-
cluded interventions that are not used widely in western
countries, but have been shown to be effective, such as
nortriptyline and cytisine. An additional novel feature of
this review is the estimation of reach and effectiveness of
interventions speciﬁcally on quit attempts and quit success.
This was necessary for the EQUIPT model, but more
generally provides useful information for tobacco control
strategy development in different countries that wish to
focus attention on these different parts of the quitting
process.
Implications of ﬁndings
Combining the quit attempt and quit success effectiveness
estimates can be used to generate an estimate of effect of
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Table 1 Interventions included in the analysis.
Intervention Speciﬁcation Justiﬁcation for speciﬁcation
(a) Interventions to increase the quit attempt rate
Increases in
taxation
Increasing taxation and implementing countermeasures to
prevent illicit supply resulting in an increase in the average
cost of smoking 5% above the cost of living index
Increasing taxation by itself need not lead to a rise
in the cost of smoking because of multiple methods
of mitigating the impact, and the evidence
speciﬁcally focuses on the ﬁnancial cost of smoking,
not on taxation on its own
Ban on smoking in
indoor public areas
A comprehensive ban on smoking in all indoor public
areas, including bars, together with mass media
campaigns and enforcement to ensure near 100%
compliance
The evidence base relates to bans of this kind. Partial
bans or bans that are not complied with appear to have
little or no impact
Mass media
campaigns
Provision of verbal messaging and imagery about
smoking and stopping smoking constructed in
accordance with principles set out in Public Health
England communication strategy document or
equivalent; sufﬁcient activity, primarily TV, to
accumulate 400 gross rating points (a standard measure
of average per-capita advertising exposure commonly
used in evaluations of televised campaigns combining
reach and frequency); between 4 and 10 weeks during
the year
Evidence suggests that mass media campaigns need to be
a minimum intensity and sustained over a minimum
period in order to have a detectable effect. The term
‘social marketing’ is used in the EQUIPT model but it
should be noted that social marketing (e.g. use of social
media) that goes beyond mass media campaigns has
not been evaluated adequately
Brief physician
advice
Provision of advice to stop smoking with discussion
about the best available options for stopping according to
principles set out in NCSCT brief advice training; taking
up to 5 minutes; delivered by physician trained to NCSCT
standard; provided opportunistically to all smokers
attending the surgery at least once a year
Evidence suggests that brief opportunistic advice including
offer of support has a greater effect than advice alone, and
need only take a few minutes
NRT for ‘reduce
to quit’
Provision of NRT to smokers interested in stopping
smoking but not willing to quit within the next few
weeks; to support them to reduce their smoking with a
view to quitting in the succeeding weeks
The RCTs on which this intervention description is based
included smokers who were motivated to quit but not
within the next few months
(b) Interventions to increase success of quit attempts
Single-form NRT Provision of one of the many forms of NRT (chewing
gum, transdermal patch, lozenge, sublingual tablet,
nasal spray, inhalator, mouth spray); typically enough to
deliver > 1 mg nicotine per hour systematically; starting
on the target quit date and continuing for 8 weeks;
provided in person by health professional, retailer or by
post; instructed by health professional on use, effects and
side effects; free or minimal cost to user; used by smokers
of at least 10 cigarettes per day making a quit attempt
The speciﬁcation describes the intervention as it has been
assessed in RCTs. No clear difference has been found
between different forms of NRT. Evidence from real-world
studies suggests that NRT may not be effective if bought
from a shop without any health professional being
involved or additional materials provided [32]
Dual form NRT Provision of nicotine transdermal patch together with
one of the faster acting forms; typically daily patch plus
ad lib use of additional product; starting on the target quit
date and continuing for 8 weeks; delivered in person by
health professional, retailer or by post with instruction by
health professional on use, effects and side-effects; free or
minimal cost to user; used by smokers of at least 10
cigarettes per day making a quit attempt
The speciﬁcation describes the intervention as it has been
assessed in RCTs. Evidence from real-world studies
suggests that NRT may not be effective if bought from a
shop without any health professional being involved or
additional materials provided [32]
Varenicline
(Champix)
Provision of varenicline (Champix) 0.5 mg twice daily for
1 week then 1 mg twice daily for 11 weeks; starting at
least 1 week prior to target quit date with a total
treatment duration of 12 weeks; delivered by health
professional on prescription with instruction by health
professional on use, effects and side-effects; free or
minimal cost to user; used by smokers of at least 10
cigarettes per day making a quit attempt
The speciﬁcation describes the intervention as it has been
delivered in RCTs. The effect size is conﬁrmed by real-world
studies [33,34]
(Continues)
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Table 1. (Continued)
Intervention Speciﬁcation Justiﬁcation for speciﬁcation
Varenicline
(extended duration)
As above but provided for 24 weeks instead of 12 The speciﬁcation describes the intervention as it has been
delivered in a large RCT [35]
Bupropion (Zyban) Provision of bupropion 150 mg once daily for 6 days,
then 150 mg twice daily for 6–8 weeks; starting 1–
2 weeks prior to target quit date with a total treatment
duration of 7–9 weeks; delivered in person by health
professional on prescription; with instruction by health
professional on use, effects and side effects; free or
minimal cost to user; used by smokers of at least 10
cigarettes per day making a quit attempt
The speciﬁcation describes the intervention as it has been
delivered in RCTs
Nortriptyline Provision of nortriptyline (generic) 75–100 mg per day
titrated to therapeutic levels for depression using serum
concentrations; starting 1–2 weeks prior to target quit
rate with total treatment duration of 12–14 weeks;
delivered in person by health professional on prescription
with instruction by health professional on use, effects
and side effects; free or minimal cost to user; used by
smokers of at least 10 cigarettes per day making a quit
attempt
The speciﬁcation describes the intervention as it has been
delivered in RCTs
Cytisine Provision of cytisine (generic; available brands: Tabex
and Desmoxan) 100 1.5 mg tablets in total; six tablets
per day for 3 days, then 5 tablets per day for 9 days, then
four tablets per day for 4 days, then three tablets per day for
4 days, then one to two tablets per day for 5 days;
starting up to 1 week before target quit date and
continuing for 25 days; delivered in person by health
professional on prescription with instruction by health
professional on use, effects and side effects; free or
minimal cost to user; used by smokers of at least 10
cigarettes per day making a quit attempt
The speciﬁcation describes the intervention as it has been
delivered in RCTs
Behavioural
support (face-to-
face, individual)
Provision of practical advice and emotional support and
encouragement based on Maudsley model; typically
weekly sessions, 1 h for ﬁrst session then approximately
30 minutes on average after that; usually starting
2 weeks before the quit date and continuing for at least
4 weeks afterwards; delivered in person by a health
professional trained to NCSCT standard or equivalent;
provided in an ofﬁce or clinic setting in-person by a single
practitioner to a single client or patient; premises,
equipment and infrastructure support and supervision
for practitioner, including ongoing monitoring of
outcomes as per Public Health England Service and
Monitoring Guidance or equivalent; free or low cost to
user; used by smokers making a quit attempt during the
year
The speciﬁcation is derived from analysis of the
characteristics of interventions evaluated in RCTs
supplemented by detailed analysis of the components of
specialist services provided routinely in the United
Kingdom through the National Health Service
Behavioural
support (face-to-
face, group)
Group discussion based on Maudsley model; typically
weekly sessions, 90 minutes for ﬁrst session then
approximately 60 minutes on average after that; usually
starting 2 weeks before the quit date and continuing for
at least 4 weeks afterwards; led by one or two health
professionals trained to NCSCT standard or equivalent;
provided in a clinic setting to groups of between six and
30 smokers; premises, equipment and infrastructure
support and supervision for practitioner, including
ongoing monitoring of outcomes as per NHS Service and
The speciﬁcation is derived from analysis of the
characteristics of interventions evaluated in RCTs
supplemented by detailed analysis of the components of
specialist services provided routinely in the UK through
the National Health Service
(Continues)
24 Robert West et al.
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 113 (Suppl. 1), 19–31
Table 1. (Continued)
Intervention Speciﬁcation Justiﬁcation for speciﬁcation
Monitoring Guidance or equivalent; free or low cost to
user smokers making a quit attempt
Behavioural
support (telephone,
pro-active)
Provision of practical advice and emotional support and
encouragement; 30–60 minutes for ﬁrst session then
approximately 15–30 minutes on average after that;
usually starting before the quit date and continuing for at
least 4 weeks afterwards; delivered by a health
professional; free or low cost to the user; used by smokers
making a quit attempt
The speciﬁcation is derived from interventions evaluated
in RCTs However, the speciﬁcs are less clear than for
face-to-face support because there is less evidence from
real-world settings and some large studies have failed to
show a beneﬁt for this kind of support but it is not clear
why [36]
Behavioural
support (text
messaging)
Automated provision of practical advice and
encouragement; multiple texts daily, tapering off after
1 month; usually starting up to 1 week prior to target
quit date and continuing for at least 4 weeks afterwards;
delivered by automated system; free or low cost to user;
used by smokers making a quit attempt
The speciﬁcation is based on evidence from RCTs. No
evidence is available from real-world evaluations
Behavioural
support (printed
materials)
Provision of practical advice and encouragement
involving either one-off book/booklets or multiple
booklets; usually one-off or delivered over a period of up
to 12 weeks following the target quit date; provided by
health professional or health promotion agency free of
charge; provided in the absence of face-to-face support;
used by smokers making a quit attempt
The speciﬁcation is based on evidence from RCTs. No
evidence is available from real-world evaluations
NCSCT= National Centre for Smoking Cessation and Training (www.ncsct.org); NRT = nicotine replacement therapy; EQUIPTmodel = return on investment
model for smoking cessation interventions in European countries; RCT = randomized controlled trial.
Table 2 Smoking cessation interventions excluded from the analysis.
Intervention Speciﬁcation Reason for exclusion
Bans on tobacco
advertising [37]
Bans on tobacco advertising vary in form and scope. In
general. they prohibit marketing through particular
channels such as television, ﬁlm, posters or point-of-sale
displays
Although it is possible that thesewould promote smoking
cessation, it is not possible at this point to arrive at a
reliable estimate of the effect size
Warnings on
cigarette packets
[38]
Text and/or pictorial warnings on cigarette packets about
the health effects of smoking
Although it is possible that thesewould promote smoking
cessation, it is not possible at this point to arrive at a
reliable estimate of the effect size
Standardized
packaging [39]
Requirement for cigarette and hand-rolled tobacco
packaging to conform to a ﬁxed standard in terms of
colours, fonts, size and shape, with no brand imagery
Although it is possible that this would promote smoking
cessation, it is not possible at this point to arrive at a
reliable estimate of the effect size
NRT (preloading)
[40]
Starting to use NRT for 2 or more weeks prior to the
target quit date
Although there is some evidence that this improves
success rates compared with starting NRT use on the quit
date, the data are not yet sufﬁciently strong to warrant
inclusion
Electronic
cigarettes [41]
Devices that use an electrical element to heat a liquid
containing glycerol or propylene glycol, usually nicotine
and often ﬂavourings to produce a vapour that is inhaled.
These vary widely in design and nicotine delivery
Although there is some evidence that these can help
smokers to stop, the data are not yet sufﬁciently strong or
consistent to permit a conﬁdent estimation of precise
effect size. This is likely to change in the near future
Behavioural
support (internet)
[42]
Websites and digital mobile applications designed to help
smokers to stop
Although there are websites that have been found to aid
smoking cessation, none of these are available and ones
that are available have not been evaluated adequately. To
date no ﬁrm evidence of the effectiveness of digital mobile
applications is available
NRT = nicotine replacement therapy.
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interventions on cessation, and these estimates can be
combinedwith reach estimates to arrive at ﬁgures for inter-
vention impact. The Supporting information ﬁle contains
an Excel spreadsheet with these calculations for England.
In modelling the impact of combinations of interventions
(e.g. mass media campaigns plus provision of single-form
NRT), some additional assumptions need to be made. The
most important of these is that the intervention effects
are independent of each other, and so the ratios
representing effect sizes combine multiplicatively. Another
is that the effect and reach are independent of each other.
For example, if amassmedia campaign leadsmore smokers
Table 3 Estimated reach and effect size of smoking cessation interventions.
(a) Interventions to promote quit attempts
Intervention Reacha
Effect
sizeb Rationale
Increases in taxation [43] 100% 1.20 Based on consumption elasticity of0.4 with assumption half of this being due
to quitting and attributing all of this to an increase in incidence of quit attempts
Ban on smoking in public indoor
areas [44]
100% 1.10c Based on study of effect of English smoking ban on quit attempt rates at the time
it was implemented
Mass media campaigns [45,46] 100% 1.03c Based on data on association between gross rating points and prevalence
reduction in England, assuming that the reduction is achieved through an
increase in quit attempts
Brief opportunistic advice by a
physician [47]
21% 1.40 Based on analysis of Cochrane Review speciﬁcally assessing effect on attempts to
stop
Nicotine replacement therapy (NRT)
for ‘reduce to quit’ [48,49]
12% 2.10c Based on systematic review of RCTs of NRT for ‘reduce to quit’ supplemented by
real-world effectiveness estimate in England
(b) Interventions to improve success rates of quit attempts
Intervention Reachd
Effect
sizee Rationale
Single form nicotine replacement
therapy (NRT) [40]
5% 1.60 Based on Cochrane review of NRT for smoking cessation supplemented by real-
world effectiveness estimate in England
Dual form nicotine replacement
therapy (NRT) [34,40]
2% 2.14 Synthetic estimate based on Cochrane review of single form NRT versus placebo
multiplied by dual form NRT versus single form, supplemented by real-world
effectiveness estimate in England
Varenicline [34,50,51] 5% 2.24 Based on Cochrane review supplemented by EAGLES trial and real-world
effectiveness estimates in England
Varenicline (extended duration) [50] 1% 2.76 Synthetic estimate based on Cochrane review of varenicline versus placebo
multiplied by effect in comparison of extended versus standard duration
treatment
Bupropion [52] 1% 1.60 Based on Cochrane Review of bupropion for smoking cessation
Nortriptyline [52] 0%f 2.00 Based on Cochrane Review of nortriptyline for smoking cessation
Cytisine [50] 0%f 3.98g Based on Cochrane Review of cytisine for smoking cessation
Behavioural support (individual)
[32,53,54]
2% 1.40 Based on Cochrane review of individual behavioural support for smoking
cessation, supplemented by real-world evidence in England
Behavioural support (group) [34,55] 1% 1.88g Based on Cochrane review of group-based behavioural support for smoking
cessation, supplemented by real-world evidence in England
Telephone support (proactive) [56] 0.5% 1.37g Based on Cochrane review of pro-active support for smoking cessation
Text messaging [57,58] 0.5% 1.63g Based on most recent meta-analysis of text messaging support for smoking
cessation
Printed materials [59] 1% 1.19g Based on Cochrane review of printed self-help materials for smoking cessation
aReach refers to the proportion of smokers in England that are currently estimated to be exposed to the intervention. bEffect size refers to the ratio of the prev-
alence of smokers who would be expected to make a quit attempt in a given year if the intervention were implemented compared with the rate if it were not
implemented, other things being equal. Effect sizes are point estimates and subject to both a margin of error because of sampling variation in the studies, and
also true variation as a function of variation in the delivery of the intervention. cEstimate should be viewed with caution because of probably wide margin of
error or variation due to implementation. dReach refers to the proportion of smokers in England who currently make a quit attempt in a given year who are
exposed to the intervention. eEffect size refers to the ratio of the proportion of smokers exposed to the intervention who are estimated to achieve 12months of
smoking abstinence compared with not receiving the intervention, other things being equal. Effect sizes are point estimates and subject to both a margin of
error because of sampling variation in the studies, and also true variation as a function of variation in the delivery of the intervention. fNortriptyline and
cytisine are not used in England but are available in other countries. gEstimate should be viewed with caution because of likely wide margin of error or var-
iation due to implementation. See Table 4 for caveats. RCT = randomized controlled trial.
26 Robert West et al.
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 113 (Suppl. 1), 19–31
Table 4 Caveats attaching to reach and effect size estimates of smoking cessation interventions.
Intervention Caveat
Increases in taxation Most of the evidence on the impact of taxation uses cigarette consumption as an outcome rather than
smoking cessation. The estimate is dependent upon the tax increase leading to an increase in the cost
of smoking. Evidence from a number of jurisdictions indicates that the effect of tax increases are often
mitigated by pricing strategies of tobacco companies or actions by smokers such as trading down to
cheaper products. Evidence does not support the claim by tobacco companies that raising taxes
increases the purchase of illicit tobacco; the latter appears to be driven more by lax enforcement or
increased opportunities for tax evasion. It is possible that at least part of the impact of tax increases is
on the success of quit attempts, but evidence is lacking on this
Ban on smoking in indoor public
areas
Different countries have implemented indoor smoking bans differently and that appears to have been
associated with differences in their impact on smoking. It appears that comprehensive bans that are
accompanied by strong publicity campaigns to secure popular support are important in securing
adherence and motivating quit attempts. Evidence suggests that these bans have a one-off effect
around the time they are introduced. It is possible that at least part of the impact of indoor smoking
bans is on the success of quit attempts, but evidence is currently lacking on this
Mass media campaigns Mass media campaigns can be expected to vary substantially in their effectiveness depending on the
content, intensity, patterning of delivery. The estimate provided here is based on traditional TV
campaigns but other models are possible, e.g. setting up annual quitting events such as Stoptober
[60]. It is possible that at least part of the impact of mass media campaigns is on the success of quit
attempts [61]. There is currently insufﬁcient evidence to estimate effect sizes for social marketing
campaigns using digital media
Brief physician advice The effectiveness of different types of advice may differ according to context. England has an extensive
network of free stop-smoking behavioural support and stop-smoking medicines are reimbursed. This
means that physicians only need offer support and refer to a specialist or provide a prescription. If
smokers have to pay for treatment, the offer may be less effective. It is not clear whether brief advice
from other health professionals has the same effect as from physicians
NRT for ‘reduce to quit’ It is not clear whether it is enough just to advise smokers who are not ready to stop to use NRT to help
them cut down, or whether they need to be supervised and set a clear smoking reduction target in
anticipation of setting a quit date in a few weeks or months.
Single-form NRT The evidence is strongand consistent that this increases the chances of quittingwhen used as part of a
structured support programme but population data in England have found no evidence for a beneﬁt
when smokers simply buy NRT from a shop
Dual-form NRT The effect-size estimate is a synthetic estimate based on data from placebo-controlled trials of single
NRT forms with data from comparisons between single-form NRT and dual-form NRT
Varenicline (Champix) The effectiveness of varenicline appears to be very similar across different contexts and in different
populations. Concerns about serious neuropsychiatric and cardiovascular side effects have not been
supported by evidence from RCTs or very large observational studies. However, there has been
relatively little research assessing the impact of varenicline in the absence of a structured behavioural
support programme.
Varenicline (extended duration) This is mainly based on one study [35]. It is possible that the extended dose improved outcomes
speciﬁcally for smokers who did not manage to quit on their target quit date but managed to quit later
during the initial treatment period [62]
Bupropion (Zyban) The effectiveness of bupropion appears to be robust in multiple contexts but has not been tested in the
absence of structured behavioural support
Nortriptyline The conﬁdence intervals on nortriptyline are wide because there are relatively few studies. This is a
very inexpensive medication but needs careful monitoring by a health professional because of risk of
overdose
Cytisine The conﬁdence intervals on cytisine arewide because there are still relatively few studies. It is not clear
whether it is more effective than other pharmacotherapies but one large open-label study found it to
be superior to NRT in the context of a telephone support programme
Behavioural support (face-to-
face, individual)
The evidence base for behavioural support is strong, but it is very difﬁcult to estimate effect sizes
because typically the comparison condition in studies also involves active support, and the more
intensive the intervention condition typically the more intensive the comparison condition. The
content and delivery of the behavioural support programme makes a difference to outcomes so it is
important that the programmes conform to accepted standards and that they are delivered by
appropriately trained and supervised staff [63–66]. There is some suggestion that the added beneﬁt of
(Continues)
Effectiveness and reach estimates of smoking cessation interventions 27
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 113 (Suppl. 1), 19–31
to try to quit, increasing the reach of interventions aimed
at increasing quit success rates, this does not inﬂuence
the effects of those interventions.
An example ROI model (http://roi.equipt.eu) and its
country applications using the data presented here are
described elsewhere [68–71]. The ROI tools help decision-
makers to simulate the health and economic beneﬁts com-
pared to implementation costs under various investment
scenarios; our reach and effect-size estimates, therefore,
are also useful ingredients to potential FCTC investment
cases. The EQUIPT study has evaluated transferability of
our estimates from England to other jurisdictions [72].
Study limitations
The most important limitation of this review is that its
effect-size and reach estimates relate to speciﬁc contexts
and implementations when in practice there will be large
variation in both of these. Therefore, judgements will al-
ways need to be made as to whether, in a context to which
the ROI model is being applied, the estimates are too high
or too low. It would therefore be prudent to undertake
sensitivity analyses using higher or lower values of the
estimates to assess the relative impact of different combina-
tions of interventions under different assumptions. One
such analysis conducted has suggested that our estimates
could provide the much-needed input data in countries
where context-speciﬁc reach and effectiveness data are ei-
ther not available or cannot be collected due to resource
constraints [72]. Undertaking sensitivity analyses will also
be important to address the issue of varying conﬁdence in
the effect-size estimates themselves. Thus, cytisine has a
very large effect-size estimate relative to other medications,
but with much fewer data.
The review is also limited by the fact that each
intervention’s effect is estimated separately, and we do
not have good information on interactions between
interventions. The ROI modelling assumes that combining
behavioural support and medication results in an effect
that is the multiple of the effect-size ratios of the
components. The Cochrane review of behavioural support
interventions suggests that this may not be valid, but we do
not know. Neither do we know whether adding a
mass media campaign to a tax increase leads to either or
both interventions having a greater effect, a smaller effect
or neither.
Future research
The effect-size and reach estimates in this paper will need
to be updated as new ﬁndings emerge. It is problematic that
very fewcountries have the kind of evidence needed to gen-
erate estimates speciﬁc to their context. The Framework
Convention on Tobacco Control mandates countries that
are party to the treaty to undertake the kind of population
monitoring that would generate this kind of evidence [73],
so it is to be hoped that more countries will begin to comply
with this commitment.
CONCLUSIONS
Tax increases, indoor smoking bans, brief opportunistic
physician advice and use of NRT for smoking reduction
can all increase population quit attempt rates. Quit success
rates can be increased by provision of NRT, varenicline,
bupropion, nortriptyline, cytisine and behavioural support
delivered through a variety of modalities. These interven-
tions can all make a contribution to national and regional
strategies for increasing population smoking cessation
rates. More countries need to collect the kind of data
needed to be able to assess context-speciﬁc parameters
relating to smoking cessation to inform ROI models or
use the data presented in this paper after an assessment
of transferability.
Table 4. (Continued)
Intervention Caveat
behavioural support when given with stop smoking medication may be less than when it is the only
treatment being provided [53] but this is not clearly the case
Behavioural support (face-to-
face, group)
Although the effect-size estimate for group-based support is higher than for individual support, and
success rates for group-based programmes in England tend to be higher than for individual
programmes, studies directly comparing the two have not shown group support to be superior [55]
Behavioural support (telephone,
proactive)
The effect size varies widely across studies and this form of support can present logistical difﬁculties
when it comes to providing stop-smoking medicines
Behavioural support (text
messaging)
Evidence from the largest of the RCTs suggests that the effect may only be present in people not using
stop-smoking medication [67]
Behavioural support (printed
materials)
Studies to date have found that the effect is greater for tailored materials and is limited to contexts in
which no other form of support is being used [59]
NRT = nicotine replacement therapy; RCT = randomized controlled trial.
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